Further analysis demonstrated that CCL1 activates the MAPK pathway in CCR8-transfected CHO cells. The implication of this pathway was confirmed by the fact that PD98059, an inhibitor of MEK kinases, as well as a dominant negative isoform of the M-RAS protein specifically blocked the anti-apoptotic activity of CCL1.

2025年2月1日 · Recent studies show that CCR8 is a well-recognized marker of activation for TI-Treg cells in mice and humans, and is possibly responsible for Treg cell functions, ... CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apoptotic activity of I-309/ CCL1 and vMIP-I. Eur. J. Immunol., 33 (2003), pp. 494-501.

2025年1月30日 · Recent studies demonstrate that CC chemokine receptor (CCR)8 is highly and specifically expressed on effector TI-Treg cells in mice and humans, highlighting CCR8 as a promising target for selective TI-Treg cell depletion in the treatment of various cancers.

CCR8. CCR8（Chemokine receptor 8）是一种七跨膜G蛋白偶联受体，属于趋化因子受体C-C亚家族。CCR8在Th2细胞、单核细胞和NK细胞上有表达，在Th1细胞上不表达。此外，CCR8在Treg细胞中也有表达，在肿瘤浸润的Treg细胞中高表达，在胸腺、脾脏和外周血的Treg细胞中表达量较低。

We show that CCL1 and vMIP-I induce ERK1/2 phosphorylation, that CCR8 stimulation activates the MAP-kinase path-way, and that the effect of CCL1 is blocked by an inhibi-tor of this pathway and by a dominant negative RAS iso-form, demonstrating the role of the RAS/MAP-kinase pathway in this anti-apoptotic activity.

2024年4月29日 · CC族趋化因子受体8（CC chemokine receptor 8，CCR8）属于CC族趋化因子受体家族，其主要在肿瘤微环境中的Treg细胞上特异性高表达，而在周围正常组织和外周血中低表达，因此CCR8可以作为Treg细胞的一种特异性标志物，是一种有潜力的治疗靶点和生物标志物。 本文对近年来CCR8在不同瘤种中的研究进展进行了归纳和总结，以期为后续研究提供参考。 [关键词] 肿瘤；CC族趋化因子受体8；免疫治疗；靶向治疗.

We show that CCL1 and vMIP-I induce ERK1/2 phosphorylation, that CCR8 stimulation activates the MAP-kinase pathway, and that the effect of CCL1 is blocked by an inhibitor of this pathway and by a dominant negative RAS isoform, demonstrating the role of the RAS/MAP-kinase pathway in this anti-apoptotic activity.

2024年2月3日 · 2月2日，上海科技大学iHuman研究所徐菲团队在国际学术期刊《科学进展》(Science Advances) 上发表题为“Unveiling the structural mechanisms of nonpeptide ligand recognition and activation in human chemokine receptor...

综上，ccr8靶点作用机制独特，有望成为肿瘤免疫治疗的下一代重磅药物靶点，因此ccr8靶向药开发前景较好。 目前全球尚无CCR8靶向药获批上市，随着相关研究不断深入，有业内人士表示，CCR8靶向药有望于2026年左右进入市场，届时将为肿瘤患者提供更多的治疗 ...

Recent studies demonstrate that CC chemokine receptor (CCR)8 is highly and specifically expressed on effector TI-Treg cells in mice and humans, highlighting CCR8 as a promising target for selective TI-Treg cell depletion in the treatment of various cancers.